Specifications tableSubject areaCardiologyMore specific subject areaElectrocardiologyType of dataTables and figures of analyzed dataHow data was acquiredReview of health records and automated measurements provided by computerized electrocardiogram interpretation softwareData formatAnalyzedExperimental factorsPaired wide complex tachycardia and subsequent baseline electrocardiograms were acquired within clinical settings at the Mayo Clinic Rochester or Mayo Clinic Health System of South Eastern Minnesota between September 2011 and November 2016.Experimental featuresIn a two-part investigation, a logistic regression model (i.e. WCT Formula), comprised of computerized electrocardiogram measurements and novel computations, was derived and validated using two separate patient cohorts.Data source locationMayo Clinic, Rochester MNData accessibilityFeatured data within this article.Related research articleMay, A. M., C. V. DeSimone, A. H. Kashou, D. O. Hodge, G. Lin, S. Kapa, S. J. Asirvatham, A. J. Deshmukh, P. A. Noseworthy, and P. A. Brady. 2019. 'The WCT Formula: A novel algorithm designed to automatically differentiate wide-complex tachycardias\', *J Electrocardiol*, 54: 61--68.**Value of the data**○Data would be valuable to researchers interested in specifying desired clinical and electrocardiogram (ECG) features to be evaluated in prospective studies which aim to accurately differentiate ventricular tachycardia (VT) and supraventricular wide complex tachycardia (SWCT).○Data would be valued by researchers interested in understanding patient demographics, clinical characteristics and electrocardiographic features of wide complex tachycardia (WCT) events encountered in clinical practice.○Enclosed data summarizes the patient demographics, clinical characteristics and ECG laboratory interpretation data of patient cohorts used to derive and validate the WCT Formula.○Enclosed data details the distribution of shared and non-shared WCT diagnoses between the WCT Formula, ECG laboratory interpretation and clinical diagnosis.○Enclosed data summarizes electrocardiographic characteristics of WCTs erroneously classified by the WCT Formula.

1. Data {#sec1}
=======

[Table 1](#tbl1){ref-type="table"} describes the clinical and ECG laboratory diagnosis data for the derivation cohort. Most (86.1%) clinical diagnoses were established by heart rhythm or non-heart rhythm cardiologists. A sizeable majority (91.8%) of WCTs were assigned definitive or probable interpretive diagnoses by the ECG laboratory. More than half of evaluated WCTs (51.4%) were derived from patients who underwent an electrophysiology procedure and/or possessed an implantable intra-cardiac device.Table 1Derivation cohort: Clinical and ECG laboratory diagnosis.[a](#tbl1fna){ref-type="table-fn"}Table 1SWCT (n = 160)VT (n = 157)P valueDiagnosing ProviderHeart rhythm cardiologists70 (43.8)147 (93.6)\<0.001Non-Heart rhythm cardiologists51 (31.9)5 (3.2)Non-cardiologists39 (23.4)5 (3.2)Time Separation between WCT and Baseline ECG (hours)Mean (SD)601.2 (2975.91)176.7 (704.1)0.54Median12.29.7Q1, Q31.4, 60.51.0, 53.4Range0.0--29800.20.0--5307.5Time Separation between WCT and Baseline ECG\<3 hours58 (36.3)64 (40.8)0.413--24 hours43 (26.8)32 (20.4)0.171--30 days41 (25.6)55 (35.0)0.07\>= 30 days18 (11.3)6 (3.8)0.01ECG Lab InterpretationDefinite VT5 (3.1)122 (77.7)\<0.001Probable VT13 (8.1)20 (12.7)Definite SWCT115 (71.9)3 (1.9)Probable SWCT10 (6.3)3 (1.9)Undifferentiated17 (10.6)9 (5.7)Electrophysiology ProcedureYes24 (15.0)81 (51.6)\<0.001Implantable DeviceYes20 (12.5)109 (69.4)\<0.001[^1]

[Table 2](#tbl2){ref-type="table"} summarizes the patient characteristics of the derivation cohort. The SWCT group included fewer ECG pairs from patients with coronary artery disease, prior myocardial infarction, prior cardiac surgery, ongoing antiarrhythmic drug use, ischemic cardiomyopathy, non-ischemic cardiomyopathy, and implanted cardioverter-defibrillator. Baseline ECGs with ventricular pacing were more common in the VT group. Preexisting bundle branch block was more prevalent in the SWCT group.Table 2Derivation cohort: Clinical characteristics .[a](#tbl2fna){ref-type="table-fn"}Table 2SWCT (n = 160)VT (n = 157)P valueAge (years) Mean (SD)71.5 (13.3)66.1 (13.6)0.002 Range22--9830--90GenderMale99 (61.9)127 (80.9)\<0.001Female61 (38.1)30 (19.1)Clinical CharacteristicsCoronary artery disease77 (48.1)103 (65.6)0.002Prior myocardial infarction44 (27.5)88 (56.1)\<0.001Prior cardiac surgery52 (32.5)71 (44.2)0.02Congenital heart disease7 (4.4)14 (8.9)0.10Anti-arrhythmic drug use16 (10.0)95 (60.5)\<0.001Ischemic cardiomyopathy29 (18.1)74 (47.1)\<0.001Non-ischemic cardiomyopathy39 (24.4)54 (34.4)0.05AICD7 (4.4)106 (67.5)\<0.001Pacemaker13 (8.1)3 (1.9)0.01Left Ventricular Ejection Fraction (%)LVEF (\>= 50)90 (56.3)33 (21.0)\<0.001LVEF (49--31)25 (15.6)46 (29.3)LVEF (\<= 30)42 (26.3)78 (49.7)Unknown LVEF3 (1.9)0 (0.0)Baseline ECGBaseline bundle branch block102 (63.8)27 (17.2)\<0.001Baseline ventricular pacing10 (6.3)69 (44.0)\<0.001[^2]

[Table 3](#tbl3){ref-type="table"} describes the clinical and ECG laboratory diagnosis data for the validation cohort. Most (85.2%) clinical diagnoses were established by heart rhythm or non-heart rhythm cardiologists. Nearly all (98.2%) interpreted WCTs were assigned definitive or probable diagnoses by the ECG laboratory. A minority (31.0%) of evaluated WCTs were derived from patients who underwent an electrophysiology procedure. A sizable fraction (35.6%) of evaluated WCTs possessed an implantable intra-cardiac device.Table 3Validation cohort: Clinical and ECG laboratory diagnosis.[a](#tbl3fna){ref-type="table-fn"}Table 3SWCT (n = 168)VT (n = 116)P valueDiagnosing ProviderHeart rhythm cardiologists71 (42.3)101 (87.1)\<0.001Non-Heart rhythm cardiologists58 (34.5)12 (10.3)Non-cardiologists39 (23.2)3 (2.6)Time Separation between WCT and Baseline ECG (hours)Mean (SD)172.7 (900.8)137.8 (522.2)0.42Median5.05.4Q1, Q30.7, 28.21.0, 45.3Range0.02--10097.10.1--4383.9Time Separation between WCT and Baseline ECG\<3 hours76 (45.2)47 (40.5)0.433--24 hours45 (26.8)31 (26.7)0.991--30 days37 (22.0)32 (26.6)0.28\>= 30 days10 (6.0)6 (5.2)0.78ECG Lab InterpretationDefinite VT5 (3.0)104 (89.7)\<0.001Probable VT3 (1.8)6 (5.2)Definite SWCT150 (89.3)3 (2.6)Probable SWCT6 (3.6)2 (1.7)Undifferentiated4 (2.4)1 (0.9)Electrophysiology ProcedureYes27 (16.1)61 (52.6)\<0.001Implantable DeviceYes29 (17.3)72 (62.1)\<0.001[^3]

[Table 4](#tbl4){ref-type="table"} summarizes the patient characteristics of the validation cohort. The VT group included more ECG pairs from patients with coronary artery disease, prior myocardial infarction, ongoing antiarrhythmic drug use, ischemic cardiomyopathy, and implanted cardioverter-defibrillator. The SWCT included more ECG pairs from patients with an implanted pacemaker lacking cardioverter-defibrillator capability. Baseline ECGs with ventricular pacing were more common in the VT group. Preexisting bundle branch block was more prevalent in the SWCT group.Table 4Validation cohort: Clinical characteristics.[a](#tbl4fna){ref-type="table-fn"}Table 4SWCT (n = 168)VT (n = 116)P valueAge (years) Mean (SD)69.8 (15.8)65.4 (12.4)\<0.001 Range18--9227--88GenderMale113 (67.3)98 (85.5)0.001Female55 (32.7)18 (15.5)Clinical CharacteristicsCoronary artery disease83 (49.4)85 (73.3)\<0.001Prior myocardial infarction49 (29.2)69 (59.5)\<0.001Prior cardiac surgery71 (42.3)47 (40.5)0.77Congenital heart disease11 (6.6)5 (4.3)0.42Anti-arrhythmic drug use36 (21.4)70 (60.3)\<0.001Ischemic cardiomyopathy23 (13.7)64 (55.2)\<0.001Non-ischemic cardiomyopathy38 (22.6)35 (30.2)0.15AICD15 (8.9)70 (60.3)\<0.001Pacemaker14 (8.3)2 (1.7)0.02Left Ventricular Ejection Fraction (%)LVEF (\>= 50)99 (58.9)36 (31.0)\<0.001LVEF (49--31)34 (20.2)39 (33.6)LVEF (\<= 30)24 (14.3)40 (34.5)LVEF Unknown11 (6.6)1 (0.9)Baseline ECGBaseline bundle branch block115 (68.5)12 (10.3)\<0.001Baseline ventricular pacing9 (5.4)41 (35.3)\<0.001[^4]

[Table 5](#tbl5){ref-type="table"} provides a comparative analysis of clinical and ECG laboratory interpretation data for the derivation and validation cohorts. The validation cohort included more WCTs with definitive or probable interpretive diagnoses coded by the ECG laboratory (validation cohort: 98.2% vs. derivation cohort: 91.8%).Table 5Derivation vs. Validation Cohort: Clinical and ECG Laboratory Diagnosis.[a](#tbl5fna){ref-type="table-fn"}Table 5Derivation Cohort (n = 317)Validation Cohort (n = 284)P valueDiagnosing ProviderHeart rhythm cardiologists217 (68.5)172 (60.6)0.08Non-Heart rhythm cardiologists56 (17.7)70 (24.7)Non-cardiologists44 (13.9)42 (14.8)Time Separation between WCT and Baseline ECG (hours)Mean (SD)391.0 (2178.5)158.5 (768.1)0.03Median10.75.2Q1, Q31.2, 53.40.8, 40.5Range0.0--29800.20.02--10097.1Time Separation between WCT and Baseline ECG\<3 hours122 (38.5)123 (43.3)0.233--24 hours75 (23.7)76 (26.8)0.381--30 days96 (30.3)69 (24.3)0.10\>= 30 days24 (7.6)16 (5.6)0.34ECG Lab InterpretationDefinite VT127 (40.1)109 (38.4)\<0.001Probable VT33 (10.4)9 (3.2)Definite SWCT118 (37.2)153 (53.9)Probable SWCT13 (4.1)8 (2.8)Undifferentiated26 (8.2)5 (1.8)Electrophysiology ProcedureYes105 (33.1)88 (31.0)0.58Implantable DeviceYes129 (40.7)101 (35.6)0.20[^5]

[Table 6](#tbl6){ref-type="table"} provides a comparative summary of the patient characteristics for the derivation and validation cohorts. The derivation cohort included more ECG pairs from patients with severely reduced LVEF (\<30%). The derivation cohort included more ECG pairs with a ventricular paced baseline heart rhythm.Table 6Derivation vs. Validation Cohort: Patient Characteristics.[a](#tbl6fna){ref-type="table-fn"}Table 6Derivation Cohort (n = 317)Validation Cohort (n = 284)P valueAge (years) Mean (SD)68.8 (13.7)68.0 (14.6)0.93 Range22--9818--92GenderMale226 (71.3)211 (74.3)0.41Female91 (28.7)73 (25.7)Clinical CharacteristicsCoronary artery disease180 (56.8)168 (59.2)0.56Prior myocardial infarction132 (41.6)118 (41.6)0.98Prior cardiac surgery123 (38.8)118 (41.6)0.49Congenital heart disease21 (6.6)16 (5.6)0.61Anti-arrhythmic drug use111 (35.0)106 (37.3)0.56Ischemic cardiomyopathy103 (32.5)87 (30.6)0.62Non-ischemic cardiomyopathy93 (29.3)73 (25.7)0.32AICD113 (35.7)85 (29.9)0.14Pacemaker16 (5.1)16 (5.6)0.75Left Ventricular Ejection Fraction (%)LVEF (\>= 50)123 (38.8)135 (47.5)\<0.001LVEF (49--31)71 (22.4)73 (25.7)LVEF (\<= 30)120 (37.9)64 (22.5)Unknown LVEF3 (1.0)12 (4.3)Baseline ECGBaseline bundle branch block129 (40.7)127 (44.7)0.32Baseline ventricular pacing79 (24.9)50 (17.6)0.03[^6]

[Table 7](#tbl7){ref-type="table"} summarizes the electrocardiographic characteristics of SWCTs erroneously classified as VT by the WCT Formula\'s 50% VT probability partition.Table 7Electrocardiographic characteristics of clinical VTs classified as SWCT by the WCT Formula\'s 50% VT probability partition.[a](#tbl7fna){ref-type="table-fn"}Table 7WCT Formula DiagnosisClinical DiagnosisECG Laboratory DiagnosisWCT Formula VT Probability (%)Frontal PAC (%)Horizontal PAC (%)Baseline ECG QRS DurationBaseline ECG Frontal QRS axis (°)Baseline ECG V1 QRS MorphologyBaseline ECG V6 QRS MorphologyBaseline ECG Precordial TransitionWCT QRS Duration (ms)WCT Frontal QRS axis (°)WCT V1 QRS MorphologyWCT V6 QRS MorphologyWCT Precordial TransitionSWCTVTProbable SWCT48.43846.650111.071116−8rSqRV614057rSRSV6SWCTVTDefinite VT47.65128.42453.163136−15RSRRSV2184−32RQRsNoneSWCTVTDefinite VT47.24224.64280.93518852rSRV416872rSqRV4SWCTVTDefinite VT44.54844.399108.675170−86RrSV3140−63RRSNoneSWCTVTDefinite VT31.68399.14981.05098−18rSqRV4124−51QSRsV2SWCTVTDefinite VT26.86835.82685.22388−38rSqRsV2146−36rSQSV4SWCTVTDefinite VT23.13465.97275.96411874rSqRV513629QSRV3SWCTVTDefinite VT18.81437.40778.68484−61rSRSV4142−81RRSV5SWCTVTDefinite VT18.503114.12248.91213218rSqRsV3126−45rSrqrSV2SWCTVTDefinite VT6.29065.53055.60614084rSrRsV412481QSRV2SWCTVTDefinite VT3.56081.15219.608110−51rSrRSV6130−28QSRSV5SWCTVTDefinite VT3.12529.76549.641110−59rSqRsV3132−61QSRSV5[^7]

[Table 8](#tbl8){ref-type="table"} summarizes the electrocardiographic characteristics of VTs erroneously classified as SWCT by the WCT Formula\'s 50% VT probability partition.Table 8Electrocardiographic characteristics of clinical SWCTs classified as VT by the WCT Formula\'s 50% VT probability partition.[a](#tbl8fna){ref-type="table-fn"}Table 8WCT Formula DiagnosisClinical DiagnosisECG Laboratory DiagnosisWCT Formula VT Probability (%)Frontal PAC (%)Horizontal PAC (%)Baseline ECG QRS DurationBaseline ECG Frontal QRS axis (°)Baseline ECG V1 QRS MorphologyBaseline ECG V6 QRS MorphologyBaseline ECG Precordial TransitionWCT QRS Duration (ms)WCT Frontal QRSaxis (°)WCT V1 QRS MorphologyWCT V6 QRS MorphologyWCT Precordial TransitionVTSWCTDefinite VT99.940146.000221.877104129rSqrsV5146−76rSqRV6VTSWCTDefinite SWCT99.405144.474157.844158−82QSQSNone150118rsRRSNoneVTSWCTDefinite VT89.67997.65667.8338622rSRsV3180−62rSqRsV5VTSWCTDefinite SWCT88.95384.193142.417136−43QSqRsV513870rSRV5VTSWCTDefinite SWCT81.050118.900104.65617463QSRV5136−28qRRSNoneVTSWCTDefinite SWCT78.88984.32062.144122−8rSqRV5176−52rSRsrV6VTSWCTDefinite SWCT77.68084.17385.9231181rSqRV4160−35rSRSV6VTSWCTDefinite SWCT67.78796.30496.36810010rSRsV314056RRNoneVTSWCTDefinite SWCT61.86429.959105.085168−28QSRV6160−70rSrSNoneVTSWCTDefinite SWCT60.85223.00880.273118−46rSRSV5178−52rSrSNoneVTSWCTDefinite SWCT56.49897.28241.79910819rSqRV5166−37rSrSrNoneVTSWCTDefinite SWCT51.74062.59448.899154−19QSRV5174−58QSQrSNone[^8]

[Fig. 1](#fig1){ref-type="fig"} summarizes the distribution of shared and non-shared WCT diagnoses between (1) the WCT Formula\'s 50% VT probability partition, (2) clinical diagnosis and (3) ECG laboratory interpretation. The WCT Formula\'s agreement with VT diagnoses established by either or both the ECG laboratory and clinical diagnosis was 91.4% and 85.3%, respectively. The WCT Formula\'s agreement with SWCT diagnoses established by either or both the ECG laboratory interpretation and clinical diagnosis was 93.5% and 86.9%, respectively.Fig. 1**Diagnostic Agreement**. Venn diagrams summarizing the distribution of VT (A) and SWCT (B) diagnoses established by (1) WCT Formula\'s 50% VT probability partition, (2) clinical diagnosis and (3) ECG laboratory interpretation. Undifferentiated WCT diagnoses (n = 5) established by the ECG laboratory are not shown.Fig. 1

2. Experimental design, materials, and methods {#sec2}
==============================================

A recent study by May and colleagues details the development and validation of a logistic regression model capable of automatic VT probability estimation [@bib1]. In a two-part investigation, a logistic regression model (i.e. WCT Formula) was derived and validated using two separate patient cohorts. In Part 1, a derivation cohort of paired WCT and subsequent baseline ECGs was examined to identify independent VT predictors to be incorporated into the WCT Formula. In Part 2, the WCT Formula\'s performance was prospectively evaluated against a validation cohort of paired WCT and subsequent baseline ECGs. The derivation cohort was comprised of 317 paired WCT (157 VT, 160 SWCT) and baseline ECGs. The validation cohort consisted of 284 paired WCT (116 VT, 168 SWCT) and baseline ECGs. The diagnostic performance of the WCT Formula was appraised according to its agreement with clinical and/or ECG laboratory diagnosis.

Paired WCT and subsequent baseline ECGs were acquired within clinical settings at the Mayo Clinic Rochester or Mayo Clinic Health System of South Eastern Minnesota between September 2011 and November 2016. Evaluated ECGs were standard, 12-lead recordings (paper speed: 25 mm/s, voltage calibration: 10 mm/mV) acquired from our institution\'s centralized ECG data archives (*GE Healthcare;* Milwaukee, WI). Data relating to clinical diagnosis, ECG laboratory interpretation and patient characteristics were recorded from the electronic medical record. Automated ECG measurements were accessed from *GE Healthcare\'s* MUSE ECG interpretation software. Novel computations, including frontal and horizontal percent amplitude change (PAC) ([Fig. 2](#fig2){ref-type="fig"}), were calculated using automated measurements derived from paired WCT and subsequent baseline ECGs.Fig. 2**Frontal and Horizontal PAC Calculations,** The frontal and horizontal PAC calculations are composed of measured QRS waveform amplitudes (μV) derived from select ECG leads within the frontal or horizontal plane. *LeadX* denotes individual ECG leads within the frontal (aVR, aVL, aVF) or horizontal (V1, V4, V6) ECG plane. Positive Amplitude (PA) is the sum of measured QRS waveform amplitudes above the isoelectric baseline (*r/R* and *r'/R′*) in a single ECG lead. Negative Amplitude (NA) is the sum of measured QRS waveform amplitudes below the isoelectric baseline (*q/QS*, *s/S*, and *s'/S′*) in a single ECG lead. Total Baseline Amplitude (TBA) is the sum of PA and NA within individual ECG leads of the baseline ECG. Baseline Amplitude (BA) is the summation of TBAs from select ECG leads in the frontal (aVR, aVL, aVF) or horizontal (V1, V4, V6) ECG planes. Absolute Positive Change (APC) and Absolute Negative Change (ANC) are an individual ECG lead\'s absolute QRS amplitude change above and below the isoelectric baseline, respectively. Total Amplitude Change (TAC) is the sum of APC and ANC within an individual ECG lead. Absolute Amplitude Change (AAC) is the combined sum of TACs from select ECG leads of the frontal (aVR, aVL, aVF) or horizontal (V1, V4, V6) ECG planes. Percent Amplitude Change (PAC) is the percent ratio of AAC to BA.Fig. 2
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[^1]: Numbers in parentheses are percent (%) of n or standard deviation. SD = standard deviation; SWCT = supraventricular tachycardia; VT = ventricular tachycardia.

[^2]: Numbers in parentheses are percent (%) of n or standard deviation. AICD = automatic implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; SD = standard deviation; SWCT = supraventricular tachycardia; VT = ventricular tachycardia.

[^3]: Numbers in parentheses are percent (%) of n or standard deviation. SD = standard deviation; SWCT = supraventricular tachycardia; VT = ventricular tachycardia.

[^4]: Numbers in parentheses are percent (%) of n or standard deviation. AICD = automatic implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; SD = standard deviation; SWCT = supraventricular tachycardia; VT = ventricular tachycardia.

[^5]: Numbers in parentheses are percent (%) of n or standard deviation. SD = standard deviation; SWCT = supraventricular tachycardia; VT = ventricular tachycardia.

[^6]: Numbers in parentheses are percent (%) of n or standard deviation. AICD = automatic implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; SD = standard deviation; SWCT = supraventricular tachycardia; VT = ventricular tachycardia.

[^7]: ECG = electrocardiogram; PAC = percent amplitude change; SWCT = supraventricular wide complex tachycardia; VT = ventricular tachycardia; WCT = wide complex tachycardia.

[^8]: ECG = electrocardiogram; PAC = percent amplitude change; SWCT = supraventricular wide complex tachycardia; VT = ventricular tachycardia; WCT = wide complex tachycardia.
